glp-1 agonist and heart failure The Cardiovascular Biology of Glucagon-like Peptide-1 It's important to study the

Weghuber D, Barrett T, Barrientos-Prez M et al (2022) Once-weekly semaglutide in adolescents with obesity

Future research must address these gaps, focusing on long-term safety, optimizing combination approaches, and evaluating the broader clinical and economic implications of widespread GLP-1 RA use

(2025) 16:1517272/FULL

Gastrointestinal side effects such as nausea and vomiting are more frequently reported with oral semaglutide, says Dr

After setbacks in internal oral GLP-1 development, Pfizer moved to strengthen its position through acquisition activity, including its move for Metsera and its next-generation obesity portfolio